Botanix Pharmaceuticals Limited (BXPHF) reported a 45% increase in revenue for the fourth quarter of 2026 compared to the same period last year, according to an earnings call transcript. Despite the revenue growth, the company's shares slipped during trading, with some sources indicating the stock fell near its lows.
During the earnings call, Botanix discussed its Quarterly Activity, Cash Flow, and the Commercial Progress of Sofdra for Primary Axillary Hyperhidrosis, a condition involving excessive underarm sweating.
45%
Increase in Botanix's Q4 2026 revenue year-over-year.